K. Tarte, F. Zhan, D. Vos, J. Klein, B. Shaughnessy et al., Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation, Blood, vol.102, issue.2, pp.592-600, 2003.
DOI : 10.1182/blood-2002-10-3161

J. Jung, J. Choe, L. Li, and Y. Choi, Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10, European Journal of Immunology, vol.30, issue.8, pp.2437-2443, 2000.
DOI : 10.1002/1521-4141(2000)30:8<2437::AID-IMMU2437>3.0.CO;2-M

T. Kobata, C. Morimoto, and A. Komiyama, Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction, Blood, vol.91, pp.173-180, 1998.

L. Glimcher, H. Baumann, L. Malek, and R. Hawley, Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells, Int J Oncol, vol.15, pp.173-178, 1999.

T. Hirano and T. Kishimoto, Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor, Science, vol.241, pp.825-828, 1988.

R. Zinkernagel, H. Bluethmann, and G. Köhler, Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, vol.368, pp.339-342, 1994.

E. Gravallese, D. Friend, M. Grusby, F. Alt, and L. Glimcher, Plasma cell differentiation requires the transcription factor XBP-1, Nature, vol.412, pp.300-307, 2001.

T. Hirano, Interleukin 6 and its Receptor: Ten Years Later, International Reviews of Immunology, vol.17, issue.4, pp.249-284, 1998.
DOI : 10.1016/0092-8674(87)90437-5

O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto, Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma, Nature, vol.332, pp.83-85, 1988.

R. Bataille, Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989.

X. Zhang, R. Bataille, J. Widjenes, and B. Klein, Interleukin-6 dependence of advanced malignant plasma cell dyscrasias, Cancer, vol.78, issue.6, pp.1373-1376, 1992.
DOI : 10.1002/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1

C. Clement, B. Morel-fournier, Z. Lu, P. Mannoni, J. Sany et al., Murine anti- interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, vol.78, pp.1198-1204, 1991.

J. Brochier and B. Klein, Biologic effects of anti-interleukin-6 (IL-6) murine monoclonal antibody in advanced multiple myeloma, Blood, vol.86, pp.685-691, 1995.

Z. Lu, H. Brailly, J. Wijdenes, R. Bataille, J. Rossi et al., Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments

R. Bataille, J. M. Zhang, X. Klein, and B. , Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias., Journal of Clinical Investigation, vol.84, issue.6
DOI : 10.1172/JCI114392

T. Kishimoto, T. Klein, and B. , Increased and highly stable levels of functional soluble interleukin, p.6

D. Maraninchi, M. Piechaczyk, R. Bataille, and B. Klein, In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma, Eur.J.Immunol, vol.21, pp.1759-1762, 1991.

V. Costes, M. Portier, Z. Lu, J. Rossi, R. Bataille et al., Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production, British Journal of Haematology, vol.76, issue.4, pp.1152-1160, 1998.
DOI : 10.1038/332083a0

R. Hinson, J. Williams, and E. Shacter, Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2., Proceedings of the National Academy of Sciences, vol.93, issue.10
DOI : 10.1073/pnas.93.10.4885

H. Uchiyama, B. Barut, A. Mohrbacher, D. Chauhan, and K. Anderson, Adhesion of

R. Bataille and B. Klein, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

K. Yamamura, T. Hirano, and T. Kishimoto, IgG1 plasmacytosis in interleukin-6 transgenic mice

T. Kishimoto and T. , Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice, Proc.Natl.Acad.Sci.U.S.A, vol.89, pp.232-235, 1992.

T. Taga, T. Kishimoto, R. Bataille, and B. Klein, Ciliary neurotropic factor, interleukin 11, leukemia inbitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130, J.Exp.Med, vol.179, pp.1337-1342, 1994.

B. Klein, Growth factors in the pathogenesis of multiple myeloma, In: Garthon L

M. Jourdan, X. Zhang, M. Portier, J. Boiron, R. Bataille et al., IFN-alpha induced autocrine production of IL-6 in myeloma cell lines, J.Immunol, vol.147, pp.4402-4407, 1991.

M. Ferlin-bezombes, J. M. Liautard, J. Brochier, J. Rossi, J. Klein et al., IFNalpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis, J Immunol, vol.161, pp.2692-2699, 1998.

T. Arora and D. Jelinek, Differential Myeloma Cell Responsiveness to Interferon-alpha Correlates with Differential Induction of p19INK4d and Cyclin D2 Expression, Journal of Biological Chemistry, vol.273, issue.19, pp.11799-11805, 1998.
DOI : 10.1074/jbc.273.19.11799

J. Rossi and B. Klein, Interleukin-10 is a growth factor for human myeloma cells, Blood, vol.85, pp.2521-2527, 1995.

J. Rossi and B. Klein, Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop, Blood, vol.88, pp.3972-3986, 1996.

D. Vos, J. , J. M. Tarte, K. Jasmin, C. Klein et al., JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells, British Journal of Haematology, vol.83, issue.4, pp.823-828, 2000.
DOI : 10.1073/pnas.94.13.6764

M. Jourdan, J. Vos, N. Mechti, and B. Klein, Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1, Cell Death and Differentiation, vol.7, issue.12, pp.1244-1252, 2000.
DOI : 10.1038/sj.cdd.4400758

URL : https://hal.archives-ouvertes.fr/inserm-00130981

G. Ciliberto, L. Moscinski, J. Fernandez-luna, G. Nunez, W. Dalton et al., Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, vol.10, pp.105-115, 1999.

M. Amiot, Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells, Blood, vol.100, pp.194-199, 2002.

Y. Tu, A. Gardner, and A. Lichtenstein, The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses, Cancer Res, vol.60, pp.6763-6770, 2000.

L. Pfeffer, J. Mullersman, S. Pfeffer, A. Murti, W. Shi et al., STAT3 as an Adapter to Couple Phosphatidylinositol 3-Kinase to the IFNAR1 Chain of the Type I Interferon Receptor, Science, vol.276, issue.5317, pp.1418-1420, 1997.
DOI : 10.1126/science.276.5317.1418

C. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama et al., Activation of NF-??B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications, Oncogene, vol.21, issue.37, pp.5673-5683, 2002.
DOI : 10.1038/sj.onc.1205664

Y. Qiang, E. Kopantzev, and S. Rudikoff, Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk, Blood, vol.99, issue.11
DOI : 10.1182/blood.V99.11.4138

D. Bouscary, Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma, Oncogene, vol.21, pp.6587-6597, 2002.

N. Mechti and B. Klein, Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, pp.771-780, 2001.

B. Klein and J. Dore, A plasmocyte selective monoclonal antibody (B-B4) recognizes

P. Zimmermann and G. David, The syndecans, tuners of transmembrane signaling

K. Davis-fleischer and G. Besner, Structure and function of heparin-binding EGFlike growth factor (HB-EGF), Front Biosci, vol.3, pp.288-299, 1998.

N. Normanno, C. Bianco, D. Luca, A. Salomon, and D. , The role of EGF-related peptides in tumor growth, Frontiers in Bioscience, vol.6, issue.3, pp.685-707, 2001.
DOI : 10.2741/A635

J. Mendelsohn and J. Baselga, The EGF receptor family as targets for cancer therapy, Oncogene, vol.19, issue.56
DOI : 10.1038/sj.onc.1204082

C. Seidel, M. Borset, I. Turesson, N. Abildgaard, A. Sundan et al., Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group, Blood, vol.91, pp.806-812, 1998.

A. Sundan, Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease, Blood, vol.94, pp.3883-3888, 1999.

H. Avet-loiseau, J. Li, T. Facon, C. Brigaudeau, N. Morineau et al., High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies, Cancer Res, vol.58, pp.5640-5645, 1998.

T. Rasmussen, H. Hudlebusch, L. Knudsen, and H. Johnsen, FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance, British Journal of Haematology, vol.90, issue.3, pp.626-628, 2002.
DOI : 10.1046/j.1365-2141.1999.01770.x

C. Kawamura, M. Kizaki, N. Shimada, Y. Ote, J. Hata et al., Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity, Jpn J Cancer Res, vol.93, pp.459-466, 2002.

K. Hart, S. Robertson, and D. Donoghue, Identification of Tyrosine Residues in Constitutively Activated Fibroblast Growth Factor Receptor 3 Involved in Mitogenesis, Stat Activation, and Phosphatidylinositol 3-Kinase Activation, Molecular Biology of the Cell, vol.12, issue.4, pp.931-942, 2001.
DOI : 10.1091/mbc.12.4.931

P. Bergsagel, Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma, Blood, vol.97, pp.729-736, 2001.

J. Pollett, S. Trudel, D. Stern, Z. Li, and A. Stewart, Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance, Blood, vol.100, issue.10, pp.3819-3821, 2002.
DOI : 10.1182/blood-2002-02-0608

F. Mackay and S. Kalled, TNF ligands and receptors in autoimmunity: an update, Current Opinion in Immunology, vol.14, issue.6
DOI : 10.1016/S0952-7915(02)00407-7

F. Mackay and J. Browning, BAFF: A fundamental survival factor for B cells, Nature Reviews Immunology, vol.2, issue.7, pp.465-475, 2002.
DOI : 10.1038/nri844

E. Cukerman, O. Francisco-pabalan, C. Liew, J. Woodgett, and A. Stewart, A molecular compendium of genes expressed in multiple myeloma, Blood, vol.100, pp.2175-2186, 2002.

K. Tarte, J. Moreaux, E. Legouffe, J. Rossi, and B. Klein, BAFF is a Survival Factor for Multiple Myeloma Cells, Blood, 2002.

J. French, D. Walters, and D. Jelinek, Transactivation of gp130 in Myeloma Cells, The Journal of Immunology, vol.170, issue.7
DOI : 10.4049/jimmunol.170.7.3717

D. Walters, J. French, B. Arendt, and D. Jelinek, Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-?? signaling complex, Oncogene, vol.22, issue.23
DOI : 10.1038/sj.onc.1206512

K. Podar, Y. Tai, C. Cole, T. Hideshima, M. Sattler et al., Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells, Journal of Biological Chemistry, vol.278, issue.8, pp.5794-5801, 2003.
DOI : 10.1074/jbc.M208636200

E. Rubinstein, The major CD9 and CD81 molecular partner. Identification and characterization of the complexes, J Biol Chem, vol.276, pp.14329-14337, 2001.